Search Results | Blood | American Society of Hematology

1-20 of 284

Sort by

Sort Order Select

Journal Articles

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Rami Komrokji, Virginia Volpe, Onyee Chan, Najla Al Ali, David Swoboda, Andrew Kuykendall, Eric Padron, David A. Sallman

Blood (2021) 138 (11): 989–992.

DOI: https://doi.org/10.1182/blood.2021010831

Published: 2021

Journal Articles

Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood . 2020;136(2):157-170.

Blood (2021) 137 (21): 3003.

DOI: https://doi.org/10.1182/blood.2021012067

Published: 2021

Journal Articles

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms

Justin Taylor, Xiaoli Mi, Khrystyna North, Moritz Binder, Alexander Penson, Terra Lasho, Katherine Knorr, Michael Haddadin, Bo Liu, Joseph Pangallo, Salima Benbarche, Daniel Wiseman, Ayalew Tefferi, Stephanie Halene, Yang Liang, Mrinal M. Patnaik, Robert K. Bradley, Omar Abdel-Wahab

Blood (2020) 136 (13): 1477–1486.

DOI: https://doi.org/10.1182/blood.2020006868

Published: 2020

Includes: Supplemental data

Journal Articles

SF3B1 : the lord of the rings in MDS

Laura Palomo, Francesc Solé

Blood (2020) 136 (2): 149–151.

DOI: https://doi.org/10.1182/blood.2020005719

Published: 2020

Journal Articles

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Blood (2020) 136 (2): 157–170.

DOI: https://doi.org/10.1182/blood.2020004850

Published: 2020

Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Blood (2020) 135 (26): 2402–2412.

DOI: https://doi.org/10.1182/blood.2019004492

Published: 2020

Includes: Supplemental data

Journal Articles

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

Joseph Pangallo, Jean-Jacques Kiladjian, Bruno Cassinat, Aline Renneville, Justin Taylor, Jacob T. Polaski, Khrystyna North, Omar Abdel-Wahab, Robert K. Bradley

Blood (2020) 135 (13): 1032–1043.

DOI: https://doi.org/10.1182/blood.2019002894

Published: 2020

Includes: Supplemental data

Journal Articles

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

Blood (2019) 134 (21): 1821–1831.

DOI: https://doi.org/10.1182/blood.2019001187

Published: 2019

Includes: Supplemental data

Journal Articles

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Rami S. Komrokji, MD, David A Sallman, MD, Najla Al Ali, M.Sc, Andrew T Kuykendall, MD, Chetasi Talati, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Eric Padron, MD, Alan F. List, MD

Blood (2019) 134 (Supplement_1): 3001.

DOI: https://doi.org/10.1182/blood-2019-127462

Published: 2019

Journal Articles

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Bing Li, MD, Jinqin Liu, Tiejun Qin, Zefeng Xu, MD, Gang Huang, PhD, Zhijian Xiao, MD

Blood (2019) 134 (Supplement_1): 2979.

DOI: https://doi.org/10.1182/blood-2019-126346

Published: 2019

Journal Articles

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Sunisa Kongkiatkamon, Anand Tiwari, Vera Adema, PhD, Cassandra M Kerr, MS, Bartlomiej Przychodzen, Hassan Awada, Jibran Durrani, Yvonne Parker, Drew Adams, Yuriy Fedorov, Hetty E. Carraway, MD MBA, Chao-Yie Yang, Mikkael A. Sekeres, MD MS, Daniel J. Lindner, James G Phillips, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD

Blood (2019) 134 (Supplement_1): 881.

DOI: https://doi.org/10.1182/blood-2019-128671

Published: 2019

Journal Articles

Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications

Vera Adema, PhD, Laura Palomo, Cassandra M Kerr, MS, Wencke Walter, PhD, Bartlomiej Przychodzen, Stephan Hutter, PhD, Thomas Laframboise, PhD, María Díez-Campelo, MD PhD, Mar Mallo, PhD, Aziz Nazha, MD, Blanca Xicoy, MD MSc, Manja Meggendorfer, PhD, Hetty E. Carraway, MD MBA, Claudia Haferlach, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, Torsten Haferlach, MD, Francesc Sole, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4221.

DOI: https://doi.org/10.1182/blood-2019-129292

Published: 2019

Journal Articles

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Blood (2019) 134 (Supplement_1): 4224.

DOI: https://doi.org/10.1182/blood-2019-124458

Published: 2019

Journal Articles

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

Daichi Inoue, MD PhD, Chew Guo-Liang, Bo Liu, PhD, Stanley C Lee, PhD, Brittany C Michel, Joey Pangallo, B.S., Andrew R D'Avino, Khrystyna North, Lillian E Bitner, BSc, Muran Xiao, Susumu Kobayashi, Akihide Yoshimi, MD PhD, Hana Cho, MSc, Sydney X Lu, MD PhD, Justin Taylor, MD, Cigall Kadoch, PhD, Robert K. Bradley, PhD, Omar Abdel-Wahab, MD

Blood (2019) 134 (Supplement_1): 637.

DOI: https://doi.org/10.1182/blood-2019-124616

Published: 2019

Journal Articles

SF3B1/DNMT3A Double Mutations Are Associated with Better Prognosis Than DNMT3A Mutation Alone in Myeloid Neopasms

Jinming Song, MD PhD, Mohammad Hussaini, MD, Lynn C. Moscinski, MD, Ling Zhang, MD, Xiaohui Zhang, MD PhD, Haipeng Shao, MD, Hailing Zhang, MD

Blood (2019) 134 (Supplement_1): 5029.

DOI: https://doi.org/10.1182/blood-2019-124040

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

DOI: https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS

Manja Meggendorfer, PhD, Wencke Walter, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_1): 4663.

DOI: https://doi.org/10.1182/blood-2019-126449

Published: 2019

Journal Articles

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Blood (2019) 134 (Supplement_1): 564.

DOI: https://doi.org/10.1182/blood-2019-129189

Published: 2019

Journal Articles

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Blood (2019) 134 (Supplement_1): 516.

DOI: https://doi.org/10.1182/blood-2019-129520

Published: 2019

Journal Articles

Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias

Daichi Inoue, MD PhD, Stanley C Lee, PhD, Akihide Yoshimi, MD PhD, Justin Taylor, MD, Lillian E Bitner, BSc, Atsushi Tanaka, MD, Yasutaka Hayashi, MD PhD, Hana Cho, MSc, Chie Fukui, Ruth Saganty, Alexander V Penson, PhD, Omar Abdel-Wahab, MD

Blood (2019) 134 (Supplement_1): 917.

DOI: https://doi.org/10.1182/blood-2019-124722

Published: 2019

NARROW

Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes

Malcovati L, Stevenson K, Papaemmanuil E, et al. SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood . 2020;136(2):157-170.

Single-cell genomics reveals the genetic and molecular bases for escape from mutational epistasis in myeloid neoplasms

SF3B1 : the lord of the rings in MDS

SF3B1 -mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Rare and private spliceosomal gene mutations drive partial, complete, and dual phenocopies of hotspot alterations

Genetic characterization of B-cell prolymphocytic leukemia: a prognostic model involving MYC and TP53

SF3B1 Clone Size Is an Independent Determinant for Overall Survival and Response to Treatment in Patients with Myelodysplastic Syndrome

Impact of U2AF1 Mutations on Clinical Characteristics and RNA Splicing in Myelodysplastic Syndromes (MDS)

Therapeutic Applications of a Unique Calcium Channel Blocker to Target SF3B1 MDS

Molecular Dissection of Del(5q): Distinction between Primary and Secondary Del(5q) and Pathogenetic Implications

SF3B1 Mutations Induce Oncogenic IRAK4 Isoforms and Activate Targetable Innate Immune Pathways in MDS and AML

Spliceosomal Disruption of the Non-Canonical SWI/SNF Chromatin Remodeling Complex in SF3B1 Mutant Leukemias

SF3B1/DNMT3A Double Mutations Are Associated with Better Prognosis Than DNMT3A Mutation Alone in Myeloid Neopasms

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Challenging Blast Counts By Machine Learning Techniques and Genome Sequencing for Discriminating AML and MDS

Pharmacologic Normalization of Altered Transcriptome of SF3B1 Mutant Myeloid Neoplasia

Distinct Evolutionary Patterns in Chronic Lymphocytic Leukemia (CLL) during Resistance to Graft-Versus-Leukemia (GvL)

Aberrant RNA Splicing Contributes to the Pathogenesis of EVI-Rearranged Myeloid Leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only